



Histopathology


MLC Pathology

c.scudamore@har.mrc.ac.uk

Phase 1 pathology



- IMPC Phase 1
 - Funding only to collect biobank tissues from all lines into fixative
 - Harwell - Currently tissues from most lines have been processed and embedded in wax
 - ~60 lines have been examined for histopathology
 - Lines of interest because of in vivo observations
 - Lines chosen to correlate with other tests eg clinical chemistry/NMR pilot and FACs




Phase 1 pathology results







- 57 lines examined
 - 14 lines with pathology and in vivo observations
 - 22 lines no pathology but in vivo observations recorded
 - *In vivo observations with no correlation mainly behavioural/gait*
 - 21 lines no pathology and no in vivo observations
 - *ie pathology did not detect any unexpected phenotypes*

- Tissues affected



Examples



Conclusions from phase 1



- Histopathology provides confirmation of in vivo phenotypes – less frequently detects novel phenotypes
- Data gained allows direct comparison/correlation with human disease syndromes
- In (relatively) young adult mice pathology is only likely to detect lesions in organs which are not vital for life or have significant reserve eg muscle, eyes, liver
- Light microscopy is generally not sufficiently sensitive to detect most CNS lesions ie poor correlation with behavioural tests



- Include pathology on triaged lines as part of the work package
 - To provide confirmation of phenotype and additional information
 - For nominated lines of interest for networks
- Consider the inclusion of pathology for:
 - Investigation of early neonatal mortality
 - Placental/embryonic pathology in support of imaging data in lethal phenotypes